Skip Navigation


Hum. Reprod. Advance Access originally published online on January 12, 2007
Human Reproduction 2007 22(5):1253-1259; doi:10.1093/humrep/del515
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
22/5/1253    most recent
del515v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Liu, J.
Right arrow Articles by Maruo, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, J.
Right arrow Articles by Maruo, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro

Jin Liu1, Hiroya Matsuo2, Qin Xu1, Wei Chen1, Jiayin Wang1 and Takeshi Maruo1,3

1 Department of Obstetrics and Gynecology 2 Department of Health Sciences, Kobe University Graduate School of Medicine, Kobe, Japan

3 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan. Tel: +81 78 382 6000; Fax: +81 78 382 6019; E-mail: maruo{at}kobe-u.ac.jp

BACKGROUND: This study was conducted to elucidate the effects of raloxifene on proliferation and apoptosis in cultured human uterine leiomyoma cells.

METHODS: The monolayer cultures were treated with graded concentrations (10–9, 10–8 and 10–7 M) of raloxifene and 10–7 M 17beta-estradiol (E2). Cell viability, percentage of proliferating cell nuclear antigen (PCNA)-positive cells, percentage of terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick-end labelling (TUNEL)-positive cells and the expression of PCNA and Bcl-2 proteins were assessed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxylphenyl)-2-(4-sulphophenyl)-2H-tetraz olium assay, immunocytochemistry, TUNEL assay and western blot analysis, respectively.

RESULTS: Compared with untreated cultures, the number of viable cultured cells, percentage of PCNA-positive cells and PCNA protein expression were significantly decreased by treatment with 10–9 M raloxifene, but increased by treatment with either 10–8 M or 10–7 M raloxifene. In contrast, the percentage of TUNEL-positive cells was significantly increased and Bcl-2 protein expression was significantly decreased by treatment with 10–9 M raloxifene, whereas they were not affected by treatment with either 10–8 or 10–7 M raloxifene.

CONCLUSIONS: In cultured leiomyoma cells, low concentration (10–9 M) of raloxifene may inhibit the growth of leiomyoma cells, whereas high concentrations (10–8 M, 10–7 M) of raloxifene may promote their growth.

Key words: apoptosis/leiomyoma/proliferation/raloxifene/selective estrogen receptor modulator

Submitted on June 30, 2006; resubmitted on November 3, 2006; accepted on December 12, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.